Hillard M. Lazarus

Dec 2, 2024 | nature.com | Joseph McGuirk |Leland Metheny III |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus

Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02068-3, published online 08 August 2023Following the publication of this article, the authors would like to add an additional reference as below to add context on the original discovery of PLX-R18's proposed therapeutic capabilities:16. Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Nete~ N, Aberman Z, et al.

Aug 8, 2023 | nature.com | Joseph McGuirk |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus |Leland Metheny III

AbstractPersistent cytopenia in the post-hematopoietic cell transplantation (HCT) setting can occur despite adequate engraftment of donor cells. PLX-R18, a placental-derived mesenchymal-like cell product, is expanded ex vivo in a 3-dimensional environment. PLX-R18 cells secrete a large array of hematopoietic factors, which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood.